The Relative Strength (RS) Rating for Twist Bioscience climbed into a higher percentile Wednesday, as it got a lift from 64 to 72.
This unique rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the stocks that go on to make the biggest gains often have an 80 or better RS Rating in the early stages of their moves. See if Twist Bioscience can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to establish and enter a buy zone in heavy trade.
The company reported 0% EPS growth in the latest quarterly report. Sales gains came in at 27%.
The company earns the No. 176 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
